HC Wainwright Issues Positive Forecast for Enliven Therapeutics (NASDAQ:ELVN) Stock Price

Enliven Therapeutics (NASDAQ:ELVN) had its price objective raised by HC Wainwright from $37.00 to $39.00 in a research note released on Friday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Separately, BTIG Research assumed coverage on shares of Enliven Therapeutics in a research report on Friday, December 13th. They issued a “buy” rating and a $42.00 target price for the company. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $38.75.

Enliven Therapeutics Stock Up 0.8 %

Shares of Enliven Therapeutics stock opened at $21.08 on Friday. The firm has a market cap of $1.03 billion, a PE ratio of -11.09 and a beta of 1.04. Enliven Therapeutics has a 12-month low of $15.96 and a 12-month high of $30.03. The company’s fifty day simple moving average is $21.31 and its two-hundred day simple moving average is $23.76.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings results on Thursday, March 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.07. The firm had revenue of $0.03 million during the quarter. As a group, sell-side analysts expect that Enliven Therapeutics will post -1.95 earnings per share for the current fiscal year.

Insider Transactions at Enliven Therapeutics

In related news, CFO Benjamin Hohl sold 3,350 shares of Enliven Therapeutics stock in a transaction dated Friday, December 27th. The shares were sold at an average price of $22.15, for a total transaction of $74,202.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Joseph P. Lyssikatos sold 12,500 shares of Enliven Therapeutics stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $20.61, for a total transaction of $257,625.00. Following the transaction, the insider now directly owns 1,002,688 shares of the company’s stock, valued at approximately $20,665,399.68. This trade represents a 1.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 72,784 shares of company stock valued at $1,610,375. Company insiders own 29.20% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of ELVN. Polar Capital Holdings Plc lifted its position in Enliven Therapeutics by 267.6% during the 4th quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company’s stock valued at $53,768,000 after acquiring an additional 1,739,668 shares during the period. Boxer Capital Management LLC purchased a new position in Enliven Therapeutics in the fourth quarter worth about $15,106,000. FMR LLC raised its holdings in Enliven Therapeutics by 10.6% in the third quarter. FMR LLC now owns 6,296,179 shares of the company’s stock worth $160,804,000 after buying an additional 601,611 shares during the last quarter. Lord Abbett & CO. LLC purchased a new position in Enliven Therapeutics in the third quarter worth about $8,199,000. Finally, Janus Henderson Group PLC raised its holdings in Enliven Therapeutics by 43.0% in the third quarter. Janus Henderson Group PLC now owns 1,041,724 shares of the company’s stock worth $26,611,000 after buying an additional 313,019 shares during the last quarter. 95.08% of the stock is owned by hedge funds and other institutional investors.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.